Bringing the world's first regenerated organ transplants to patients

Leadership Team

 

Tom McNaughton - serves as our Chief Financial Officer and interim Chief Executive Officer. Mr. McNaughton was the Chief Financial Officer of Harvard Bioscience since November 2008. From 2007 to 2008, Mr. McNaughton was a consultant providing services primarily to an angel-investing group and a silicon manufacturing start-up. From 2005 to 2007, Mr. McNaughton served as Vice President of Finance and Chief Financial Officer for Tivoli Audio, LLC, a venture capital-backed global manufacturer of premium audio systems. Prior to joining Tivoli Audio, LLC, from 1990 to 2005, Mr. McNaughton served in various managerial positions in the areas of financial reporting, treasury, investor relations, and acquisitions within Cabot Corporation, a global manufacturer of fine particulate products, and served from 2002 to 2005 as Finance Director, Chief Financial Officer of Cabot Supermetals, a $350 million Cabot division that provides high purity tantalum and niobium products to the electronics and semiconductor industries. Mr. McNaughton practiced from 1982 to 1990 as a Certified Public Accountant in the audit services group of Deloitte & Touche, LLP. Mr. McNaughton holds a B.S. in accounting and finance from Babson College. .

 

Saverio LaFrancesca – Chief Medical Officer... Is a cardiothoracic surgeon with extensive clinical experience committed to the clinical translation of transformative medical research. Saverio has a unique combination of experience that features over 25 years of academic clinical surgical practice and innovative research, with a foundation in the cardiovascular, thoracic transplantation, cardiac assist device and regenerative medicine fields. He joins the company from the Dept. of Cardiovascular Surgery and Transplantation at the DeBakey Heart and Vascular Center at the Houston Methodist Hospital, where he developed the current surgical and perfusion techniques for thoracic organ procurement and preservation and where he was also the Director of the Exvivo lung perfusion laboratory. Previously he was an attending surgeon at the Department of Cardiopulmonary Transplantation at the Texas Heart Institute in Houston, Texas. Saverio still holds an appointment as Associate Professor of Surgery at the University of Rome "La Sapienza” in Rome, Italy. He received his M.D. in medicine and surgery in 1985 at the University of Palermo. Saverio did his Residency in Cardiovascular Surgery in the Dept. of Cardiovascular Surgery at the University of Rome "La Sapienza". He then completed his post-doctoral training with fellowships at the Texas Heart Institute under the supervision of pioneer surgeon Denton Cooley. He was also a Clinical/ Research fellow at McGill University in Montréal, Québec, Canada and at the Baylor College of Medicine in Houston. Saverio holds UNOS certifications as heart transplant surgeon and lung transplant surgeon. He is also certified as surgeon for the use of the HeartMate and the Jarvik 2000 left ventricular assist devices.

 

Ron Sostek – Vice President of Business Development …… For over 40 years, Ron has combined his deep technical knowledge with commercial experience to identify key market needs and successfully develop and commercialize products for the scientific computing and instrumentation marketplace. Over the last 15 years, as Vice President of Business Development, he has been key in identifying and integrating companies and product lines that expanded the ability of Harvard Apparatus to meet it’s partners current requirements and future needs. As Strategic Business Manager at the IBM Scientific and Technology Group he identified and initiated programs for electronic submission of clinical trials to FDA. As Vice President of Marketing at Mettler-Toledo Ingold process analytics, he led an effort to characterize & develop an in-line sterilized probe cleaning station. As Vice President of Marketing at Bio-Rad/ Digilab he identified the need for and commercialized a MID IR imaging spectroscopy microscope. During his role of President of North American Operations of Shimadzu/ Kratos he was a key element in developing products for computerized control/acquisition/analysis of TOF/TOF SIMS MS/AUGER, & ESCA spectral and imaging instrumentation. Ron identified several market segments that allowed him as a Marketing Manager of Waters to characterize and develop instrumentation for in-line sample clean-up (multi-dimensional) / microbore, glucose and amino acid analysis systems utilizing HPLC Systems.

 

Al Correia – Vice President of Sales & Manufacturing……Previously as Vice President of Operations at Cambridge Biomedical, he was involved in all aspects of the company including Sales, Marketing, development and the laboratory where he designed and built the new laboratory facility. As Vice President of Marketing at VelQuest Corp, a provider of GMP compliance software to the pharmaceutical industry. He has presented over 50 workshops and seminars at international conferences and meetings on various compliance topics including electronic record requirements, data acquisition and Part 11. As Vice President and General Manager at Unisyn Technologies, a contract manufacturer of Pre-clinical, Phase 1 and Phase 2 therapeutics, he designed built and ran a GMP production plant. A major project completed while head of development was to design a new line of bioreactors. Prior to Unisyn, Al held several technical and marketing management positions at Zymark Corporation and was a cofounder of Xydex, a sample handling company that was acquired by Genex. He also held positions in the sales and application laboratory at Waters Associates. Al received a degree in Chemistry from the College of the Holy Cross.

 

Irina Kulinets, Ph.D., RAPS – Vice President of Quality Assurance and Regulatory Affairs. Irina brings 30+ years of extensive experience in product development and licensing within the US, European Union and other world markets, and demonstrated ability to build compliant Quality Systems that incorporate industry best practices. She joins HART after combining a position as a professor and Faculty Director of MS in Regulatory Affairs of Drugs, Biologics and Medical Devices program at Northeastern University and leading the R&C Consulting Group. At Northeastern she is teaching Regulatory and Clinical Strategy, Regulatory Intelligence, Clinical Research, Epidemiology in the development of biologic, pharmaceutical products and medical devices. R&C Consulting Group offered a comprehensive range of expert consulting services in Regulatory Affairs, Clinical Affairs, Health Economics and Quality Assurance of biotech, pharmaceuticals and medical device areas. Previously Irina held Vice President of Regulatory Affairs and Quality Systems position at Cynosure, Vice President of Regulatory and Clinical Affairs at Anika Therapeutics and was a head of Regulatory/ Clinical and Quality functions at Biosphere Medical and Omniguide, where she developed regulatory strategies for US and international product registrations and filed regulatory submissions for product registrations worldwide, while building a state-of-the-art corporate RA / CA / QA function. At TUV America she led the coordination and realization of product regulatory conformity assessment and approval of Design Dossiers for CE Marking Class III medical devices and drug /device and biologic /device combinations. She also worked for Boston Scientific Corporation and Johnson and Johnson. Irina holds a Ph.D. in Health Science from Trident University, an MSc in Quality Assurance from California State University and a MSc and BSc from The Belarus Polytechnic State University.

 

Thomas Bollenbach, Ph.D. – Vice President of Research and Development joined the company from Organogensis where he Implemented and completed efficacy and preclinical pharmacology and toxicology programs for bioengineered living skin graft in anticipation of an IND. His group developed wound healing, skin grafting, and oral regeneration models in swine which was unique in the industry for the in vivo evaluation of adult stem cell suspensions, living, bioengineered constructs and biomaterials. His ability to maintain strong cross-functional interactions with Clinical Operations ensured meaningful translation of swine studies while partnering with business units to provide scientific support to corporate strategies. Previously he was at the Boyce Thompson Institute of Cornell University where he developed expertise in molecular cloning, analysis of tissue and cells for DNA and RNA by qualitative and quantitative methods, in vitro characterization of RNA structure, in vitro translation assays, ribonuclease assays, protein-RNA interactions Tom received his BSc in biochemistry from the University of Waterloo and his Ph.D. in biochemistry from the University of Notre Dame.